PURPOSE: Because avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended for most individuals with chronic kidney disease (CKD), we sought to characterize patterns of NSAID use among persons with CKD in the United States. METHODS: A total of 12,065 adult (aged 20 years or older) participants in the cross-sectional National Health and Nutrition Examination Survey (1999-2004) responded to a questionnaire regarding their use of over-the-counter and prescription NSAIDs. NSAIDs (excluding aspirin and acetaminophen) were defined by self-report. CKD was categorized as no CKD, mild CKD (stages 1 and 2; urinary albumin-creatinine ratio of ≥ 30 mg/g) and moderate to severe CKD (stages 3 and 4; estimated glomerular filtration rate of 15-59 mL/min/1.73 m(2)). Adjusted prevalence was calculated using multivariable logistic regression with appropriate population-based weighting. RESULTS: Current use (nearly every day for 30 days or longer) of any NSAID was reported by 2.5%, 2.5%, and 5.0% of the US population with no, mild, and moderate to severe CKD, respectively; nearly all of the NSAIDs used were available over-the-counter. Among those with moderate to severe CKD who were currently using NSAIDs, 10.2% had a current NSAID prescription and 66.1% had used NSAIDs for 1 year or longer. Among those with CKD, disease awareness was not associated with reduced current NSAID use: (3.8% vs 3.9%, aware vs unaware; P=.979). CONCLUSIONS: Physicians and other health care clinicians should be aware of use of NSAIDs among those with CKD in the United States and evaluate NSAID use in their CKD patients.
PURPOSE: Because avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended for most individuals with chronic kidney disease (CKD), we sought to characterize patterns of NSAID use among persons with CKD in the United States. METHODS: A total of 12,065 adult (aged 20 years or older) participants in the cross-sectional National Health and Nutrition Examination Survey (1999-2004) responded to a questionnaire regarding their use of over-the-counter and prescription NSAIDs. NSAIDs (excluding aspirin and acetaminophen) were defined by self-report. CKD was categorized as no CKD, mild CKD (stages 1 and 2; urinary albumin-creatinine ratio of ≥ 30 mg/g) and moderate to severe CKD (stages 3 and 4; estimated glomerular filtration rate of 15-59 mL/min/1.73 m(2)). Adjusted prevalence was calculated using multivariable logistic regression with appropriate population-based weighting. RESULTS: Current use (nearly every day for 30 days or longer) of any NSAID was reported by 2.5%, 2.5%, and 5.0% of the US population with no, mild, and moderate to severe CKD, respectively; nearly all of the NSAIDs used were available over-the-counter. Among those with moderate to severe CKD who were currently using NSAIDs, 10.2% had a current NSAID prescription and 66.1% had used NSAIDs for 1 year or longer. Among those with CKD, disease awareness was not associated with reduced current NSAID use: (3.8% vs 3.9%, aware vs unaware; P=.979). CONCLUSIONS: Physicians and other health care clinicians should be aware of use of NSAIDs among those with CKD in the United States and evaluate NSAID use in their CKDpatients.
Authors: Ryne Paulose-Ram; Rosemarie Hirsch; Charles Dillon; Katalin Losonczy; Michael Cooper; Yechiam Ostchega Journal: Pharmacoepidemiol Drug Saf Date: 2003-06 Impact factor: 2.890
Authors: István Pintér; János Mátyus; Zoltán Czégány; Judit Harsányi; Marietta Homoki; Miklós Kassai; Eva Kiss; István Kiss; Erzsébet Ladányi; Lajos Locsey; Lajos Major; Mihály Misz; Lajos Nagy; Kálmán Polner; Jeno Rédl; István Solt; Béla Tichy; Marietta Török; Gábor Varga; Gyula Wagner; Imre Wórum; Béla Zsoldos; László Pótó; Katalin Dérczy; István Wittmann; Judit Nagy Journal: Nephrol Dial Transplant Date: 2004-04 Impact factor: 5.992
Authors: Tobias Kurth; Robert J Glynn; Alexander M Walker; Kathryn M Rexrode; Julie E Buring; Meir J Stampfer; Charles H Hennekens; J Michael Gaziano Journal: Am J Kidney Dis Date: 2003-08 Impact factor: 8.860
Authors: Paul E Drawz; Patrick Archdeacon; Clement J McDonald; Neil R Powe; Kimberly A Smith; Jenna Norton; Desmond E Williams; Uptal D Patel; Andrew Narva Journal: Clin J Am Soc Nephrol Date: 2015-06-25 Impact factor: 8.237
Authors: Luke S Vest; Nagaraju Sarabu; Farrukh M Koraishy; Minh-Tri Nguyen; Meyeon Park; Ngan N Lam; Mark A Schnitzler; David Axelrod; Chi Yuan Hsu; Amit X Garg; Dorry L Segev; Allan B Massie; Gregory P Hess; Bertram L Kasiske; Krista L Lentine Journal: Clin Transplant Date: 2020-06-29 Impact factor: 2.863
Authors: Min Zhan; Wendy L St Peter; Rebecca M Doerfler; Corinne M Woods; Jacob B Blumenthal; Clarissa J Diamantidis; Chi-Yuan Hsu; James P Lash; Eva Lustigova; Erin B Mahone; Akinlolu O Ojo; Anne Slaven; Louise Strauss; Jonathan J Taliercio; Wolfgang C Winkelmayer; Dawei Xie; Jeffery C Fink Journal: Clin J Am Soc Nephrol Date: 2017-08-15 Impact factor: 8.237
Authors: Janelle Guirguis-Blake; Gina A Keppel; John Holmes; Rex W Force; William Kriegsman; Laura-Mae Baldwin Journal: Fam Pract Date: 2018-09-18 Impact factor: 2.267
Authors: Min Zhan; Rebecca M Doerfler; Dawei Xie; Jing Chen; Hsiang-Yu Chen; Clarissa J Diamantidis; Mahboob Rahman; Ana C Ricardo; James Sondheimer; Louise Strauss; Lee-Ann Wagner; Matthew R Weir; Jeffrey C Fink Journal: Am J Kidney Dis Date: 2020-04-18 Impact factor: 8.860